New Zealand's Pharmac has announced it will fund Eisai's LENVIMA (lenvatinib) from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer.
Pharmac makes cancer therapy the 26th funded since budget boost
November 11, 2024 BioPharmaLatest News
Latest Video
New Stories
-
NDIS keeps growing but signs emerge that reforms are starting to work
July 17, 2025 - - Latest News -
USTR launches new investigation, with minimal ambition on pharmaceuticals
July 17, 2025 - - Latest News -
New Zealand starting to benefit after lifting advertising prohibition
July 17, 2025 - - Latest News -
Mark Butler restates support for health technology assessment reform
July 16, 2025 - - Latest News -
Brandon BioCatalyst welcomes the inclusion of its CUREator in new program
July 16, 2025 - - Australian Biotech -
Cancer Australia launches research program targeting early-onset cancers
July 16, 2025 - - Latest News -
Imugene completes significant placement and launches share purchase plan
July 16, 2025 - - Australian Biotech